Biotech Values

[Biowatch]

Zepbound could fuel LLY $600 billion empire
(If you have Apple News’s you can see the full article.)
https://www.bloomberg.com/news/features/2024-01-26/zepbound-how-eli-lilly-s-lucky-break-fueled-a-600b-weight-loss-empire

The battle over the trillion-dollar weight-loss bonanza
Novo Nordisk and Eli Lilly are making blockbuster drugs. Can they maintain their lead?

https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza

Weight-loss drugs called glp-1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens. Since June 2021, when Wegovy, the first glp-1 slimming jab, was launched in America, the market value of ww (formerly Weight Watchers) has crashed by 90%. On February 28th Oprah Winfrey announced that she would leave the dieting firm’s board and sell all her shares in order to avoid conflict of interest around her use of glp-1s. Food giants such as Nestlé are already planning for a future where the drugs dampen demand for sugary snacks. Bosses of consumer-goods firms brought up weight-loss drugs twice as often in the last full set of quarterly earnings calls, in late 2023, as they had in the previous one (see chart 1).